antiB7H3-CD3 CSANs

antiB7H3-CD3 CSANs (also known as αB7-H3-αCD3 CSANs) are multivalent, bispecific chemically self-assembling nanorings (CSANs) developed by the Wagner Lab at the University of Minnesota. This nanotechnology-based biologic is designed to redirect T cells to tumor cells by simultaneously targeting B7-H3 (CD276), a checkpoint molecule and tumor-associated antigen overexpressed in various solid tumors, and the CD3ε subunit of the T-cell receptor. The construct incorporates humanized 8H9 single-chain variable fragments (scFvs) for B7-H3 recognition. By engaging both targets, the CSANs facilitate T-cell mediated lysis of B7-H3-positive cancer cells, such as medulloblastoma and glioblastoma, independent of MHC class I expression. A key feature of the CSAN platform is the ability to modulate T-cell activation and valency by adjusting the ratio of monomers within the self-assembled nanoring structure. Preclinical studies have demonstrated the ability of these nanorings to cross the blood-tumor barrier and exhibit anti-tumor activity in intracranial xenograft models.

Other names

αB7-H3-αCD3 CSANsanti-B7-H3-anti-CD3 chemically self-assembling nanoringsanti-B-7-H3-anti-CD3 chemically self-assembling nanoringsanti-B 7-H3-anti-CD3 chemically self-assembling nanorings